CSR News Stories
Philippines: GlaxoSmithKline awarded for community programmes
GlaxoSmithKline has won two 'Anvil' awards, one for health advocacy and another for community relations. The awards, made by the Public Relations Society of the Philippines (PRSP) recognised the company's "outstanding corporate social responsibility projects".
UK: Best social and environmental reporters recognised
The Co-operative Bank has been named as the UK company that had produced the best sustainability report in the last year by the Association of Certified Chartered Accountants (ACCA) awards. Shell International was runner-up.
GlaxoSmithKline rejects SA Competition Commission findings
GlaxoSmithKline has said it rejects the charge that its prices for anti-retroviral drugs are excessive, saying that its prices are the lowest in the world.
GlaxoSmithKline clears way for new policy on pay-offs
GlaxoSmithKline has indicated that it is to move towards a remuneration policy for its executives that would avoid recent controversies over perceived pay-offs for failure.
GlaxoSmithKline launches cheap Malaria drug
GlaxoSmithKline has announced that it intends to launch a new drug to tackle a virulent form of Malaria in sub-Saharan Africa.
GlaxoSmithKline loses first round on challenge to AIDS drug patent
A district court in California has allowed a legal challenge by the Aids Healthcare Foundation aiming to remove GlaxoSmithKline's patent on AZT, the AIDS drug.
GlaxoSmithKline loses historic shareholder vote on pay
GlaxoSmithKline made UK corporate history as the first company to lose a motion on a simple majority on the company's remuneration report. 50.72 percent of shareholders voted against the report.
GlaxoSmithKline provokes fire from shareholders
GlaxoSmithKline is thought to be facing what the BBC described as "the biggest shareholder rebellion over boardroom pay ever seen in the UK" over a controversial 'golden parachute' pay package for its CEO.
GlaxoSmithKline cuts AIDS drugs prices
Just days after Calpers, the California Public Employees Retirement Scheme, called for GlaxoSmithKline to cut its price of HIV/AIDS drugs for developing countries, the company has announced that it is to do just that.
Calpers urges GlaxoSmithKline to cut AIDS drugs prices
The California Public Employees Retirement System (Calpers), the US's largest pension fund, has urged GlaxoSmithKline to review its policy of charging for AIDS drugs in developing countries.
Bayer executives accused of knowledge of serious Baycol problems
Some senior executives at Bayer have been accused of having known for some time that the company's anti-cholesterol drug Baycol had serious problems before withdrawing it from sale.
South Africa: GlaxoSmithKline faces new complaint
The largest AIDS organisation in the US, the AIDS Healthcare Foundation (AHF), has filed a complaint with the South African Competition Commission against pharmaceutical giant GlaxoSmithKline seeking to enable licensing generic alternatives for lower prices.
GlaxoSmithKline retreats on pay boost for CEO
GlaxoSmithKline hurriedly shelved plans to grant a huge pay increase for its Chief Executive Jean-Pierre Garnier following an outcry from shareholders and the media.
GlaxoSmithKline under fire again on AIDS drugs
GlaxoSmithKline is to be barred from marketing drugs at the outpatient sites of the AIDS Healthcare Foundation in protest at its pricing policies that the Foundation says put the company "outside the bounds of corporate responsibility".
GlaxoSmithKline brings cheaper drugs to the US poor
Glaxo SmithKline has announced that it is cutting the price of its drugs for large numbers of elderly US citizens - those whose low income level would give them problems in affording the treatment through other means.
GlaxoSmithKline faces lawsuit
A major class action lawsuit has been filed against pharmaceuticals giant GlaxoSmithKline on behalf of 35 people who allege they became chronically addicted to the antidepressant drug paroxetine, known as Seroxat in Britain and Paxil in the US. The lawyers involved say the action could be as big as tobacco litigation.
GlaxoSmithKline wins rare praise for pricing policy
GlaxoSmithKline's initiative to cut prices to developing countries for anti-Malaria drugs, as well as other diseases, has won praise from NGOs, including Oxfam.
The Business Respect email newsletter has been produced since 2001 to give news and commentary on CSR worldwide
See the archive of past issues
Special Feature
Social responsibility and finance - on the precipice
In a recent article, the BBC's economics editor Robert Peston highlighted the fact that in 2012 the chances are that the economy - punch drunk as it is from the various flavours of debt crisis it has been pummelled with over the course of the year - will be hit by the collapse of a major bank and / or government.
